


Plateforme de télémédecine très rentable et à forte croissance desservant le marché allemand du cannabis médical



PRINTED ON: *October 30, 2026, 8:36 PM (EST)* **PUBLISHED ON:** *March 9, 2026, 8:33 AM (EST)* **UPDATED ON:** *October 30, 2026, 7:36 PM (EST)*

MERGERSCORP

Image not found or type unknown

Plateforme de télémédecine très rentable et à forte croissance desservant le marché allemand du cannabis médical

Opportunité unique d'acquérir une plateforme de télémédecine et de prescription numérique en pleine expansion, entièrement à distance, conforme à la GDPR et opérant dans le cadre transfrontalier de l'UE. L'entreprise met en relation plus de 20 000 patients avec des médecins et des pharmacies agréés en Allemagne.

TARGET PRICE
$ 9,000,000

GROSS REVENUE
$ 1,680,000

EBITDA
$ 1,008,000

BUSINESS TYPE
Entreprises de Soins de Santé

COUNTRY
Chypre

BUSINESS ID
L#20261003

Licence(s) détenue(s)

Fonctionne dans le cadre de la télémédecine transfrontalière de l'UE (médecins agréés en Allemagne et en Pologne). Plateforme conforme au GDPR. Aucune licence de manipulation directe de cannabis n'est requise.

Détails de l'inscription

- L'entreprise chypriote exploite une plateforme de télémédecine entièrement numérique, permettant des consultations à distance et des prescriptions numériques.
- Lancée en 2024, la plateforme a servi environ 20 000 patients et traité plus de 6 500 ordonnances par mois.
- Elle s'est concentrée sur l'optimisation des processus afin de garantir l'évolutivité avant de lancer des campagnes de marketing ciblées, y compris la publicité sur Facebook et le marketing d'affiliation, et continue à mettre en œuvre de nouvelles fonctionnalités pour améliorer l'expérience de l'utilisateur.
- Activité rentable avec des marges supérieures à 60 %, un chiffre d'affaires actuel d'environ 140 000 euros par mois et une prévision de 1,5 million d'euros d'ici la fin de l'année, ce qui représente une croissance annuelle d'environ 20 %.
- Les revenus sont générés par la prise de rendez-vous avec les patients, les services de marketing pour les pharmacies, les partenariats avec des producteurs de premier plan et les offres de produits en marque blanche.
- Fonctionne efficacement avec environ 12 collaborateurs/ free-lances, en s'appuyant sur des spécialistes free-lances front-end et back-end.
- Les flux de travail automatisés réduisent le temps de consultation des médecins de 90 %, et la plateforme prend en charge des fonctionnalités en marque blanche pour une expansion B2B rapide.

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE
AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

- La croissance annuelle prévue de 15 à 20 % est due à l'augmentation de la demande des patients et à la récente libéralisation du marché allemand du cannabis.

- La vente complète est recherchée et comprend l'entreprise en activité, la propriété intellectuelle, la marque, la base de données des patients et la base de code du logiciel.

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC.A US CORPORATION WITH REGISTERED OFFICE AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM